TP53 and melanoma: Since a study on melanoma cells observed that centrinone-B was less effective in cells with mutant p53 (Denu et al. 2018), we used three ES cell lines with different TP53 status, i.e., wild-type p53 WE-68 cells, mutant p53 (C176F) SK-ES-1 cells (Sonnemann et al. 2015) and p53 null A673 cells (Ottaviano et al. 2010), to address a potential impact of p53 on the response of ES cells to PLK4 inhibition.